Based on the pool of innovations available to the Company’s research and commercialization expertise, as well as the research and medical activities of Partners HealthCare and the commercial focus of Pfizer, Boston BioCom has defined a strategic biomedical focus that encompasses a matrix of therapeutic areas and specific technologies within those areas. The company will concentrate its work in therapeutic areas that represent huge markets with significant unmet medical needs. Current areas of focus for the Company’s active programs are:
- Oncology
- Infectious Diseases
- Immune Disorders
The Company will only engage in the development of a select a manageable number of specific technologies at any given time that can have a major impact on the treatment of diseases in each of these therapeutic areas. While the initial technologies of focus are predominantly biopharmaceuticals, the range of technologies available for consideration and potential development includes:
- New Generation Therapeutic Antibodies
- Protein and Peptide-based Drugs
- Medical Devices
- Small Molecule Drugs
- Drug Delivery Technologies